Prilenia
Herzliya
About Prilenia
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $105.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2021)
- Website: prilenia.com
- Phone: +972-77-5558482
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/prilenia-70961 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.